摘要
含铂化疗、表皮因子受体-酪氨酸激酶抑制剂(EGFR-TKIs)、抗血管生成治疗、免疫治疗等单独或联合治疗均为晚期非小细胞肺癌的治疗手段。选择单药或联合用药以及联合用药的给药顺序及其效果均为晚期非小细胞肺癌临床治疗的关注热点。近年来,多位学者研究了铂类单药化疗及联合用药的疗效,研究结果不一而足,在一定程度上给临床医师选择用药方案带来了新的挑战。本文就以上相关国内外研究结果进行综述,以供临床用药、研究作参考。
Currently,platinum-based chemotherapy,EGFR-TKIs,antiangiogenic therapy and immunotherapy are applied to treat advanced non-small cell lung cancer.Selection of single or combination therapy and sequence of drugs become the focus of clinical treatment of advanced non-small cell lung cancer.In recent years,many prospective or retrospective studies have reported the efficacy of single platinum chemotherapy,or platinum-combined therapy for advanced non-small cell lung cancer.Various research results brought new challenges to some extent for clinicians to choose drug regimen.In this paper,the related research results over the world were reviewed for clinical and research reference.
作者
钟锐
邬麟
王伟
朱跃红
邱艳芳
ZHONG Rui;WU Lin;WANG Wei;ZHU Yuehong;QIU Yanfang(Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine,Central South University,Changsha,Hunan,410013,China)
出处
《肿瘤药学》
CAS
2019年第6期839-844,共6页
Anti-Tumor Pharmacy
基金
湖南省科技厅重点研发项目(2016JC2066)
关键词
含铂化疗
表皮因子受体-酪氨酸激酶抑制剂
抗血管生成治疗
免疫治疗
晚期非小细胞肺癌
Platinum-based chemotherapy
Epidermal growth factor receptor-tyrosine kinase inhibitors(EGFR-TKIs)
Antiangiogenic therapy
Immunotherapy
Advanced non-small cell lung cancer
